Literature DB >> 30871932

A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.

Lisandra Herrera Belén1, Jorge Beltrán Lissabet1, Carlota de Oliveira Rangel-Yagui2, Brian Effer1, Gisele Monteiro2, Adalberto Pessoa2, Jorge G Farías Avendaño3.   

Abstract

Acute lymphoblastic leukemia (ALL) is a type of cancer with a high incidence in children. The enzyme l-asparaginase (ASNase) constitutes a key element in the treatment of this disease. Four formulations of ASNase from a bacterial source are currently available. However, these formulations are characterized by their high immunogenicity, resulting in the inactivation of the drug, as well as in the occurrence of hypersensitivity reactions in a large number of patients. In this work, we performed an immunoinformatic analysis in order to clarify structural aspects of the immunogenicity of the asparaginase from Escherichia coli and Erwinia carotovora. For this purpose, we performed the prediction of immunogenic and allergenic epitopes in the structure of asparaginases by using the relative frequency of immunogenic peptides for the eight alleles most frequently distributed worldwide. This study showed that there are no significant differences in the level of immunogenicity between the two enzymes, while asparaginase from E. coli presented a higher relative frequency of allergenic epitopes. These results are consistent with previously published reports. However, from a structural point of view, to the best of our knowledge, this is the first report describing the structural determinants that contribute to the hypersensitivity response to this treatment.
Copyright © 2019 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute lymphoblastic leukemia (ALL); Epitope; Immunogenicity; Immunoinformatics; In silico; l-asparaginase

Mesh:

Substances:

Year:  2019        PMID: 30871932     DOI: 10.1016/j.biologicals.2019.03.003

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  5 in total

Review 1.  What makes a good new therapeutic L-asparaginase?

Authors:  Angela Beckett; David Gervais
Journal:  World J Microbiol Biotechnol       Date:  2019-09-24       Impact factor: 3.312

2.  In silico and in vitro analysis of arginine deiminase from Pseudomonas furukawaii as a potential anticancer enzyme.

Authors:  Rakhi Dhankhar; Anubhuti Kawatra; Vatika Gupta; Aparajita Mohanty; Pooja Gulati
Journal:  3 Biotech       Date:  2022-08-12       Impact factor: 2.893

Review 3.  Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy.

Authors:  Patrycja Śliwa-Tytko; Agnieszka Kaczmarska; Monika Lejman; Joanna Zawitkowska
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

4.  Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.

Authors:  Yiwei Liu; Wenjian Yang; Colton A Smith; Cheng Cheng; Seth E Karol; Eric C Larsen; Naomi Winick; William L Carroll; Mignon L Loh; Elizabeth A Raetz; Stephen P Hunger; Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Jun J Yang; William E Evans; Sima Jeha; Ching-Hon Pui; Hiroto Inaba; Mary V Relling
Journal:  Clin Pharmacol Ther       Date:  2021-04-21       Impact factor: 6.903

5.  Repurposing Tranexamic Acid as an Anticancer Agent.

Authors:  Mary E Law; Bradley J Davis; Amanda F Ghilardi; Elham Yaaghubi; Zaafir M Dulloo; Mengxiong Wang; Olga A Guryanova; Coy D Heldermon; Stephan C Jahn; Ronald K Castellano; Brian K Law
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.